AstraZeneca Expands AI Partnership with Immunai Through 2027

CryptoFrontier

AstraZeneca has expanded its partnership with New York-based AI biotech company Immunai through 2027, according to Calcalist. Under the expanded agreement, Immunai is eligible to receive up to $37.5 million in 2026 and 2027 as the drugmaker continues integrating its platform into oncology drug development programs.

Technology Platform and Applications

Imunai’s AMICA-OS platform analyzes clinical immunology data at the single-cell level. AstraZeneca said it will use the system for biomarker discovery, patient stratification, dose optimization, and mechanism-of-action analysis across its oncology programs. The companies expanded the collaboration into inflammatory bowel disease research in 2025, broadening the platform’s application beyond cancer-focused work.

Partnership Evolution

The current agreement builds on a 2024 partnership to use Immunai’s platform in oncology clinical programs. The companies’ collaboration traces back to 2022, when an initial phase focused on improving oncology trials included an $18 million investment by AstraZeneca. As of September 2024, Immunai had raised approximately $270 million in total funding. The company reported that 85 of its 170 employees hold PhD or MD degrees, and stated it has secured more than 30 partnerships with Fortune 100 drug companies and leading academic institutions.

Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to Disclaimer.

Related Articles

OpenAI Releases Three Voice Models in Realtime API; GPT-Realtime-2 Features 128K Context Window

According to Beating, OpenAI released three voice models in its Realtime API: GPT-Realtime-2 for voice conversation with reasoning, GPT-Realtime-Translate for real-time translation, and GPT-Realtime-Whisper for streaming transcription. GPT-Realtime-2 is OpenAI's first voice model with GPT-5-level re

GateNews5m ago

Google Gemini 3.1 Flash-Lite Officially Launches: Input Price 75% Cheaper Than Claude 4.5 Haiku, GPQA Score 86.9%

According to Beating, Google Gemini 3.1 Flash-Lite transitioned from preview to general availability (GA) on May 8, becoming the cheapest and fastest model in the Gemini 3 series. Input pricing is set at $0.25 per million tokens and output at $1.50 per million tokens—input costs 75% less than

GateNews21m ago

Cloudflare disappoints with its financial guidance, cuts 1,100 employees, and the stock price plunges 19% after-hours

Cloudflare’s first-quarter financial report released on Thursday showed both revenue and profit outperforming market expectations, demonstrating strong growth momentum. However, because the company’s second-quarter revenue forecast was slightly lower than analysts’ estimates, the market raised concerns about whether its growth momentum can continue. At the same time, Cloudflare announced it will lay off about 1,100 employees, representing roughly 20% of its total workforce. CEO Matthew Prince emphasized that AI and agents have become the company’s core productivity, and that its operating model is undergoing a fundamental transformation. Affected by the revenue forecast miss and news of large-scale layoffs, the company’s stock price (NET) fell nearly 19% in after-hours trading. Cloudflare disappoints on guidance, stock plunges 19% after hours Cloudflare first-quarter revenue reaches $639.8 million

ChainNewsAbmedia25m ago

SoftBank Explores AI Server Production in Japan with Nvidia, Foxconn

According to Reuters, SoftBank Group has begun talks with Nvidia and Foxconn over building AI servers in Japan. The Japanese telecom and investment group is exploring partnerships to expand its AI infrastructure business, with plans to start server design and component assembly by the end of the

GateNews28m ago

SK Hynix Receives Funding Offers from Tech Firms for AI Memory Expansion, Including 10%-30% Upfront Payments

According to Reuters, SK hynix has received funding offers from major tech companies to expand production lines for AI memory chips. The proposals include upfront payments of 10% to 30% of total contract value and financing for manufacturing equipment such as ASML extreme ultraviolet lithography

GateNews28m ago

OpenAI Launches Trusted Contacts Safety Feature Yesterday to Alert Users at Risk

OpenAI announced the launch of its Trusted Contacts safety feature on May 7. If the platform's automated systems and trained reviewers detect that an adult user may have discussed self-harm behavior posing serious safety risks, designated contacts will receive notification. The company emphasized th

GateNews48m ago
Comment
0/400
GweiGossipvip
· 1h ago
AZ and Immunai's collaboration has been extended to 2027. Thirty-seven and a half million dollars may not be an astronomical figure for AI-driven drug development, but the reduction in trial-and-error costs for the oncology pipeline can be much more than that.
View OriginalReply0
Frost-ColoredCubeCityvip
· 1h ago
Curious about the structure of this funding, is it milestone-based or platform access fee? Spreading it over the two years of 2026-2027, the burn rate pressure on Immunai won't be small.
View OriginalReply0
GateUser-6319729fvip
· 1h ago
Traditional large pharmaceutical companies are clearly accelerating their pace in AI-driven target discovery, and platforms like Immunai that have real-world data plus immune mapping are indeed rare.
View OriginalReply0